← Back to Screener
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)
Price$481.23
Value ScoreF
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-24.20%
Price vs S&P 500 (4W)-8.17%
VGM Score55.30
Market Capitalization$11.46B
All Metrics
Book Value / Share (Quarterly)$23.59
P/TBV (Annual)22.22x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-11.95
Price vs S&P 500 (YTD)-25.54%
Gross Margin (TTM)93.07%
Net Profit Margin (TTM)-27.32%
EPS (TTM)$-13.63
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$-13.63
EPS (Annual)$-12.85
ROI (Annual)-30.58%
Gross Margin (Annual)94.14%
Net Profit Margin (5Y Avg)-12793.16%
Cash / Share (Quarterly)$35.27
Revenue Growth QoQ (YoY)126.84%
ROA (Last FY)-22.89%
Revenue Growth TTM (YoY)256.82%
EBITD / Share (TTM)$-13.88
ROE (5Y Avg)-94.94%
Operating Margin (TTM)-27.93%
Cash Flow / Share (Annual)$-8.45
P/B Ratio21.10x
P/B Ratio (Quarterly)22.10x
Net Income / Employee (Annual)$-315,100
EV / Revenue (TTM)10.22x
Net Interest Coverage (TTM)-163.11x
ROA (TTM)-25.44%
EV / EBITDA (TTM)698.74x
EPS Incl Extra (Annual)$-12.85
Current Ratio (Annual)4.01x
Quick Ratio (Quarterly)2.97x
3-Month Avg Trading Volume0.34M
52-Week Price Return84.22%
Revenue / Employee (TTM)$1,237,700
Tangible BV / Share (Quarterly)$23.27
P/S Ratio (Annual)11.96x
Asset Turnover (Annual)0.76x
52-Week High$615.00
Operating Margin (5Y Avg)-12410.94%
EPS Excl Extra (Annual)$-12.85
CapEx CAGR (5Y)60.06%
Tangible BV CAGR (5Y)1.61%
26-Week Price Return-8.27%
Quick Ratio (Annual)3.62x
13-Week Price Return11.53%
Total Debt / Equity (Annual)0.56x
Current Ratio (Quarterly)3.50x
Enterprise Value$11.58B
Asset Turnover (TTM)0.93x
Book Value / Share Growth (5Y)11.25%
Revenue / Employee (Annual)$1,047,400
Pretax Margin (Annual)-30.08%
Cash / Share (Annual)$43.06
3-Month Return Std Dev41.68%
Net Income / Employee (TTM)$-338,200
ROE (Last FY)-47.83%
Net Interest Coverage (Annual)-229.75x
EPS Basic Excl Extra (Annual)$-12.85
P/FCF (TTM)150.87x
Receivables Turnover (TTM)9.10x
Total Debt / Equity (Quarterly)0.63x
EPS Incl Extra (TTM)$-13.63
Receivables Turnover (Annual)10.18x
ROI (TTM)-34.32%
P/S Ratio (TTM)10.12x
Pretax Margin (5Y Avg)-12793.16%
Revenue / Share (Annual)$42.72
Tangible BV / Share (Annual)$26.06
Forward P/E4476.11x
Price vs S&P 500 (52W)56.02%
Year-to-Date Return-14.61%
5-Day Price Return-3.86%
EPS Normalized (Annual)$-12.85
ROA (5Y Avg)-59.17%
Net Profit Margin (Annual)-30.08%
Month-to-Date Return-3.89%
Cash Flow / Share (TTM)$-19.21
EBITD / Share (Annual)$-13.43
Operating Margin (Annual)-31.60%
LT Debt / Equity (Annual)0.56x
ROI (5Y Avg)-79.76%
LT Debt / Equity (Quarterly)0.63x
EPS Basic Excl Extra (TTM)$-13.63
P/TBV (Quarterly)22.40x
P/B Ratio (Annual)21.94x
Inventory Turnover (TTM)0.94x
Pretax Margin (TTM)-27.32%
Book Value / Share (Annual)$26.39
Price vs S&P 500 (13W)1.79%
Beta-1.10x
P/FCF (Annual)460.99x
Revenue / Share (TTM)$49.15
ROE (TTM)-50.15%
52-Week Low$265.20
vGradeF
gGradeA
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-3.25est. -4.11
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.08
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MDGLMadrigal Pharmaceuticals, Inc. Common Stock | F | A | C | $481.23 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Madrigal Pharmaceuticals develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease with significant unmet medical need. Its lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor beta agonist designed to address the underlying causes of MASH and prevent progression to cirrhosis and liver failure.